Tags

Type your tag names separated by a space and hit enter

High-risk Human Papillomavirus Testing for Triage of Women with Previous Cytological Abnormalities from the Vale do Ribeira Region.
Rev Bras Ginecol Obstet. 2020 Jun; 42(6):340-348.RB

Abstract

OBJECTIVE

To evaluate the performance of the hybrid capture 2 (HC2) high-risk papillomavirus (hrHPV) assay and cytological test in women with previous abnormalities, to detect cervical intraepithelial neoplasia grade 2 or worse (≥ CIN 2).

METHODS

A cytological test and HC2 (Qiagen, Gaithersburg, Maryland, EUA) for hrHPV were conducted in 359 liquid-based (Sure Path, Becton Dickinson, TriPath Imaging, Burlington, NC, USA) samples collected from women from the Vale do Ribeira Region, during July 2013 and September 2015 with previous cytology classified as atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions (ASC-H), and atypical glandular cells (AGC). The histopathological examination was conducted in 179 women. The performance evaluations were calculated using the "exact" Clopper-Pearson 95% confidence interval (CI) test by MEDCALC (Medcalc Software Ltd, Ostend, Belgium).

RESULTS

The ≥ CIN 2 frequency was 11.7% (21/179). The HC2 for hrHPV and repeat cytology to detect ≥ CIN 2 obtained, respectively, a sensitivity of 90.5% (95%CI = 69.6-98.8) and 90.5%, (95%CI = 69.6-98.8), a specificity of 65.8% (95% CI = 57.9-73.2) and 43.7% (95%CI = 35.8-51.8), a positive predictive value of 26.0% (95% CI = 21.4-31.3) and 17.6%, (95%CI = 14.9-20.6), and a negative predictive value of 98.1% (95%CI = 93.3-99.5) and 97.2% (95% CI = 90.1-99.2).

CONCLUSION

Hybrid capture 2 for hrHPV improves the performance of the detection of ≥ CIN 2, without compromising sensitivity, and provides a greater safety margin to return to the triennial screening of women undergoing follow-up due to previous abnormalities, without underlying ≥ CIN 2.

Authors+Show Affiliations

Departamente of Pathological Anatomy, Instituto Adolfo Lutz, São Paulo, SP, Brazil.Departamente of Pathological Anatomy, Instituto Adolfo Lutz, São Paulo, SP, Brazil.Departamente of Pathological Anatomy, Instituto Adolfo Lutz, São Paulo, SP, Brazil.Departamente of Pathological Anatomy, Instituto Adolfo Lutz, São Paulo, SP, Brazil.Departamente of Pathological Anatomy, Instituto Adolfo Lutz, São Paulo, SP, Brazil.Departamente of Pathological Anatomy, Instituto Adolfo Lutz, São Paulo, SP, Brazil.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32604437

Citation

Lorente, Sandra, et al. "High-risk Human Papillomavirus Testing for Triage of Women With Previous Cytological Abnormalities From the Vale Do Ribeira Region." Revista Brasileira De Ginecologia E Obstetricia : Revista Da Federacao Brasileira Das Sociedades De Ginecologia E Obstetricia, vol. 42, no. 6, 2020, pp. 340-348.
Lorente S, Fernandes NCCA, Etlinger-Colonelli D, et al. High-risk Human Papillomavirus Testing for Triage of Women with Previous Cytological Abnormalities from the Vale do Ribeira Region. Rev Bras Ginecol Obstet. 2020;42(6):340-348.
Lorente, S., Fernandes, N. C. C. A., Etlinger-Colonelli, D., Réssio, R. A., Oliveira, S. M. P., & Catarino, R. M. (2020). High-risk Human Papillomavirus Testing for Triage of Women with Previous Cytological Abnormalities from the Vale do Ribeira Region. Revista Brasileira De Ginecologia E Obstetricia : Revista Da Federacao Brasileira Das Sociedades De Ginecologia E Obstetricia, 42(6), 340-348. https://doi.org/10.1055/s-0040-1712992
Lorente S, et al. High-risk Human Papillomavirus Testing for Triage of Women With Previous Cytological Abnormalities From the Vale Do Ribeira Region. Rev Bras Ginecol Obstet. 2020;42(6):340-348. PubMed PMID: 32604437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-risk Human Papillomavirus Testing for Triage of Women with Previous Cytological Abnormalities from the Vale do Ribeira Region. AU - Lorente,Sandra, AU - Fernandes,Natália Coelho Couto de Azevedo, AU - Etlinger-Colonelli,Daniela, AU - Réssio,Rodrigo Albergaria, AU - Oliveira,Sonia Maria Pereira de, AU - Catarino,Regina Maria, Y1 - 2020/06/30/ PY - 2020/7/1/entrez PY - 2020/7/1/pubmed PY - 2020/7/1/medline SP - 340 EP - 348 JF - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia JO - Rev Bras Ginecol Obstet VL - 42 IS - 6 N2 - OBJECTIVE: To evaluate the performance of the hybrid capture 2 (HC2) high-risk papillomavirus (hrHPV) assay and cytological test in women with previous abnormalities, to detect cervical intraepithelial neoplasia grade 2 or worse (≥ CIN 2). METHODS: A cytological test and HC2 (Qiagen, Gaithersburg, Maryland, EUA) for hrHPV were conducted in 359 liquid-based (Sure Path, Becton Dickinson, TriPath Imaging, Burlington, NC, USA) samples collected from women from the Vale do Ribeira Region, during July 2013 and September 2015 with previous cytology classified as atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions (ASC-H), and atypical glandular cells (AGC). The histopathological examination was conducted in 179 women. The performance evaluations were calculated using the "exact" Clopper-Pearson 95% confidence interval (CI) test by MEDCALC (Medcalc Software Ltd, Ostend, Belgium). RESULTS: The ≥ CIN 2 frequency was 11.7% (21/179). The HC2 for hrHPV and repeat cytology to detect ≥ CIN 2 obtained, respectively, a sensitivity of 90.5% (95%CI = 69.6-98.8) and 90.5%, (95%CI = 69.6-98.8), a specificity of 65.8% (95% CI = 57.9-73.2) and 43.7% (95%CI = 35.8-51.8), a positive predictive value of 26.0% (95% CI = 21.4-31.3) and 17.6%, (95%CI = 14.9-20.6), and a negative predictive value of 98.1% (95%CI = 93.3-99.5) and 97.2% (95% CI = 90.1-99.2). CONCLUSION: Hybrid capture 2 for hrHPV improves the performance of the detection of ≥ CIN 2, without compromising sensitivity, and provides a greater safety margin to return to the triennial screening of women undergoing follow-up due to previous abnormalities, without underlying ≥ CIN 2. SN - 1806-9339 UR - https://www.unboundmedicine.com/medline/citation/32604437/High-risk_Human_Papillomavirus_Testing_for_Triage_of_Women_with_Previous_Cytological_Abnormalities_from_the_Vale_do_Ribeira_Region L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0040-1712992 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.